Cue Biopharma (CUE) just announced preliminary data for its Phase 1A study for CUE-101 this morning.
It appears most of the information in the press release was previously shared during the company’s recent presentation at the Jefferies conference.
That said, there are several pieces of incremental and meaningful info included in this update. And management still needs to provide one more critical contextual data point for investors to fully understand the significance of the early results and in turn, properly value the stock.Click below for more details and analysis…
[Please note this post will be updated in real-time, so please keep hitting refresh]
This content is reserved for subscribers. To gain immediate access to our 100% independent research on the top tech trends and companies before they become household names, consider subscribing here.
For a limited time only you can use Coupon Code DTR50 to receive 50% off a quarterly or annual subscription.